CY1105880T1 - Χρηση μιας φαρμακευτικης συνθεσεως πepιεχουσης γαλακτικο οξυ ή γαλακτικη ριζα και καλιο για την αγωγη του εγκεφαλικου οιδηματος ή του τραυματισμου του εγκεφαλου - Google Patents
Χρηση μιας φαρμακευτικης συνθεσεως πepιεχουσης γαλακτικο οξυ ή γαλακτικη ριζα και καλιο για την αγωγη του εγκεφαλικου οιδηματος ή του τραυματισμου του εγκεφαλουInfo
- Publication number
- CY1105880T1 CY1105880T1 CY20061101847T CY061101847T CY1105880T1 CY 1105880 T1 CY1105880 T1 CY 1105880T1 CY 20061101847 T CY20061101847 T CY 20061101847T CY 061101847 T CY061101847 T CY 061101847T CY 1105880 T1 CY1105880 T1 CY 1105880T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lactic
- lactic acid
- potassium
- pharmaceutical composition
- root
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract 10
- 235000014655 lactic acid Nutrition 0.000 title abstract 5
- 239000004310 lactic acid Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010048962 Brain oedema Diseases 0.000 title 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title 1
- 208000006752 brain edema Diseases 0.000 title 1
- 208000029028 brain injury Diseases 0.000 title 1
- 229910052700 potassium Inorganic materials 0.000 title 1
- 239000011591 potassium Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
Η εφεύρεση αναφέρεται σε μία φαρμακευτική σύνθεση περιέχουσα 250 έως 2400 mmole ανά λίτρο γαλακτική ρίζα ή γαλακτικό οξύ, 2 έως 10 mmole ανά λίτρο κατιόν καλίου και προαιρετικά 2 έως 5 mmole ανά λίτρο κατιόν ασβεστίου. Η εφεύρεση αναφέρεται επίσης σε φαρμακευτικές χρήσεις αυτής της συνθέσεως. Η εφεύρεση αναφέρεται επίσης σε φαρμακευτικές χρήσεις μίας συνθέσεως εχούσης συγκέντρωση σε γαλακτικό οξύ ή γαλακτική ρίζα μεταξύ 250 και 2400 mmole ανά λίτρο.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ID20030213 | 2003-05-01 | ||
| PCT/SG2004/000066 WO2004096204A1 (en) | 2003-05-01 | 2004-03-22 | Lactate containing pharmaceutical composition and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105880T1 true CY1105880T1 (el) | 2011-02-02 |
Family
ID=33397627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101847T CY1105880T1 (el) | 2003-05-01 | 2006-12-21 | Χρηση μιας φαρμακευτικης συνθεσεως πepιεχουσης γαλακτικο οξυ ή γαλακτικη ριζα και καλιο για την αγωγη του εγκεφαλικου οιδηματος ή του τραυματισμου του εγκεφαλου |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20080125488A1 (el) |
| EP (2) | EP1759695A1 (el) |
| JP (1) | JP5037937B2 (el) |
| KR (1) | KR101076059B1 (el) |
| CN (1) | CN1777416B (el) |
| AR (1) | AR043670A1 (el) |
| AT (1) | ATE340568T1 (el) |
| AU (1) | AU2004233904B2 (el) |
| BR (1) | BRPI0409867A (el) |
| CA (1) | CA2523740C (el) |
| CY (1) | CY1105880T1 (el) |
| DE (1) | DE602004002585T2 (el) |
| DK (1) | DK1617834T3 (el) |
| EA (2) | EA013846B1 (el) |
| ES (1) | ES2274438T3 (el) |
| HK (1) | HK1085942A1 (el) |
| IL (1) | IL171721A (el) |
| MA (1) | MA27845A1 (el) |
| MX (1) | MXPA05011532A (el) |
| MY (1) | MY140382A (el) |
| NO (1) | NO20055652L (el) |
| NZ (1) | NZ543201A (el) |
| PL (1) | PL1617834T3 (el) |
| PT (1) | PT1617834E (el) |
| SG (1) | SG160217A1 (el) |
| SI (1) | SI1617834T1 (el) |
| TN (1) | TNSN05275A1 (el) |
| TW (1) | TWI290045B (el) |
| UA (1) | UA86937C2 (el) |
| WO (1) | WO2004096204A1 (el) |
| ZA (1) | ZA200509684B (el) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012766A (es) * | 2006-04-03 | 2009-01-22 | Innogene Kalbiotech Pte Ltd | Composicion farmaceutica que contiene lactato y calcio y uso de la misma. |
| JP5409596B2 (ja) | 2007-03-30 | 2014-02-05 | ラキュアー エービー | 婦人科の障害の治療における乳酸オリゴマーの使用 |
| CA2754684A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
| AU2010229668C1 (en) | 2009-03-26 | 2016-09-15 | Pulmatrix Operating Co., Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| US8758824B2 (en) | 2010-08-30 | 2014-06-24 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| ES2899621T3 (es) | 2010-09-29 | 2022-03-14 | Pulmatrix Operating Co Inc | Polvos secos catiónicos que comprenden sal de magnesio |
| RU2017144619A (ru) | 2010-09-29 | 2019-02-20 | Пулмэтрикс, Инк. | Катионы одновалентных металлов сухих порошков для ингаляций |
| ES2396650B2 (es) * | 2011-07-21 | 2013-07-16 | Universidad Complutense De Madrid | Uso de una composición en la elaboración de una solución de diálisis para el tratamiento de las enfermedades cerebrovasculares mediante diálisis peritoneal. |
| WO2013130767A1 (en) | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
| CA2872012C (en) | 2012-05-08 | 2017-06-20 | Aeromics, Llc | New methods |
| JP2015531754A (ja) * | 2012-08-01 | 2015-11-05 | ピュラック バイオケム ビー． ブイ． | 乳酸塩粉末及びそれを製造する方法 |
| US9232815B2 (en) | 2012-10-25 | 2016-01-12 | Run Them Sweet, LLC | Blood lactate range targets and nutritional formulations and protocols to support patients |
| US9808031B2 (en) | 2012-10-25 | 2017-11-07 | Run Them Sweet Llc | Systems and methods to estimate nutritional needs of human and other patients |
| US9897609B2 (en) | 2012-10-25 | 2018-02-20 | Run Them Sweet, LLC | Systems and apparatus to estimate nutritional needs of human and other patients and to support such nutritional needs |
| EP2769630B1 (en) | 2013-02-26 | 2016-04-27 | Purac Biochem N.V. | Improved nisin production process |
| EP2754356A1 (en) | 2013-01-15 | 2014-07-16 | Purac Biochem N.V. | Improved nisin production process |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| RU2691951C2 (ru) | 2013-11-06 | 2019-06-19 | Аэромикс, Инк. | Новые составы |
| WO2015182815A1 (ko) * | 2014-05-26 | 2015-12-03 | 한국생명공학연구원 | Ndrg3 발현 또는 활성 촉진제를 유효성분으로 함유하는 허혈성 질환 예방 및 치료용 약학적 조성물 |
| EP3481216B2 (en) | 2016-07-07 | 2024-03-06 | DSM IP Assets B.V. | Process for obtaining a rapeseed protein isolate and protein isolate thereby obtained |
| US10124021B2 (en) * | 2016-12-23 | 2018-11-13 | Andrew L. Gostine | Intravenous fluid |
| EP3920846A4 (en) * | 2019-02-06 | 2022-11-09 | The Board and Trustees of the Leland Stanford Junior University | BIOLOGICALLY MODIFIED VASCULAR GRAFTS FOR IMPROVED BYPASS SURGERY RESULTS |
| EP4093507A4 (en) * | 2020-01-24 | 2024-02-28 | Daniel Q Barkey | WEIGHT LOSS COMPOSITIONS AND METHODS |
| WO2023114375A2 (en) * | 2021-12-16 | 2023-06-22 | Alveolus Bio, Inc. | Inhalable or ingestible lactic acid compositions for the treatment of chronic lung disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6776887A (en) * | 1985-12-18 | 1987-07-15 | Veech, R.L. | Fluid therapy with l-lactate and/or pyruvate anions |
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| US5248507A (en) * | 1991-05-31 | 1993-09-28 | Board Of Regents, The University Of Texas System | Hypertonic isochloremic formulation for circulatory shock |
| JPH05255092A (ja) * | 1992-03-17 | 1993-10-05 | Kyowa Hakko Kogyo Co Ltd | 腸管洗浄用組成物 |
| AU681675B2 (en) * | 1993-06-04 | 1997-09-04 | Biotime, Inc. | Plasma-like solution |
| US6306828B1 (en) * | 1995-04-06 | 2001-10-23 | Baxter International, Inc. | Enantiomerically-enhanced nutritional energy substrates |
| JPH0940554A (ja) * | 1995-08-03 | 1997-02-10 | Nissho Corp | グルタミンを含む輸液及びその製造方法 |
| WO1998008500A1 (en) * | 1996-08-26 | 1998-03-05 | Board Of Regents, The University Of Texas System | Hypertonic arginine compositions and methods |
| US6436444B1 (en) * | 1997-09-26 | 2002-08-20 | Ecolab Inc. | Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection |
| CN1068778C (zh) * | 1998-05-15 | 2001-07-25 | 赵超英 | 救治用的药物组合物及其制备方法 |
| RU2136293C1 (ru) * | 1998-08-04 | 1999-09-10 | Открытое акционерное общество "Биохимик" | Способ получения заменителя плазмы крови |
-
2004
- 2004-03-22 CA CA2523740A patent/CA2523740C/en not_active Expired - Fee Related
- 2004-03-22 AT AT04722501T patent/ATE340568T1/de active
- 2004-03-22 EA EA200801073A patent/EA013846B1/ru not_active IP Right Cessation
- 2004-03-22 PL PL04722501T patent/PL1617834T3/pl unknown
- 2004-03-22 DK DK04722501T patent/DK1617834T3/da active
- 2004-03-22 EP EP06121128A patent/EP1759695A1/en not_active Withdrawn
- 2004-03-22 PT PT04722501T patent/PT1617834E/pt unknown
- 2004-03-22 NZ NZ543201A patent/NZ543201A/en not_active IP Right Cessation
- 2004-03-22 EA EA200501675A patent/EA010948B1/ru not_active IP Right Cessation
- 2004-03-22 SI SI200430136T patent/SI1617834T1/sl unknown
- 2004-03-22 UA UAA200511417A patent/UA86937C2/ru unknown
- 2004-03-22 EP EP04722501A patent/EP1617834B1/en not_active Expired - Lifetime
- 2004-03-22 SG SG200717319-8A patent/SG160217A1/en unknown
- 2004-03-22 DE DE602004002585T patent/DE602004002585T2/de not_active Expired - Lifetime
- 2004-03-22 CN CN2004800110612A patent/CN1777416B/zh not_active Expired - Fee Related
- 2004-03-22 AR ARP040100933A patent/AR043670A1/es not_active Application Discontinuation
- 2004-03-22 AU AU2004233904A patent/AU2004233904B2/en not_active Ceased
- 2004-03-22 MY MYPI20040998A patent/MY140382A/en unknown
- 2004-03-22 BR BRPI0409867-6A patent/BRPI0409867A/pt not_active IP Right Cessation
- 2004-03-22 MX MXPA05011532A patent/MXPA05011532A/es active IP Right Grant
- 2004-03-22 WO PCT/SG2004/000066 patent/WO2004096204A1/en active IP Right Grant
- 2004-03-22 JP JP2006508059A patent/JP5037937B2/ja not_active Expired - Fee Related
- 2004-03-22 US US10/555,196 patent/US20080125488A1/en not_active Abandoned
- 2004-03-22 ES ES04722501T patent/ES2274438T3/es not_active Expired - Lifetime
- 2004-03-23 TW TW093107705A patent/TWI290045B/zh not_active IP Right Cessation
-
2005
- 2005-10-24 TN TNP2005000275A patent/TNSN05275A1/en unknown
- 2005-11-01 IL IL171721A patent/IL171721A/en active IP Right Grant
- 2005-11-01 KR KR1020057020706A patent/KR101076059B1/ko not_active IP Right Cessation
- 2005-11-30 ZA ZA200509684A patent/ZA200509684B/en unknown
- 2005-11-30 NO NO20055652A patent/NO20055652L/no not_active Application Discontinuation
- 2005-12-01 MA MA28632A patent/MA27845A1/fr unknown
-
2006
- 2006-07-24 HK HK06108198A patent/HK1085942A1/xx not_active IP Right Cessation
- 2006-12-21 CY CY20061101847T patent/CY1105880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105880T1 (el) | Χρηση μιας φαρμακευτικης συνθεσεως πepιεχουσης γαλακτικο οξυ ή γαλακτικη ριζα και καλιο για την αγωγη του εγκεφαλικου οιδηματος ή του τραυματισμου του εγκεφαλου | |
| ATE534391T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| CY1113963T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| CY1113108T1 (el) | Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| BRPI0519195A2 (pt) | composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal | |
| CY1115719T1 (el) | Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
| GB0318447D0 (en) | Therapeutic agents | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
| UA90467C2 (ru) | Применение пептидных соединений для лечения боли при болезненой диабетической невропатии | |
| IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes | |
| EA200601288A1 (ru) | Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| EA200701181A1 (ru) | Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний | |
| CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| ATE504600T1 (de) | Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall | |
| CY1113310T1 (el) | Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας |